Attempting to ride booster adcomm coattails, Moderna says its Covid-19 shot is better than Pfizer/BioNTech
As the FDA prepares to convene an adcomm to discuss Pfizer/BioNTech’s Covid-19 vaccine boosters later this week, the other major mRNA player is sticking its thumb out and trying to hitch a ride on the corporate media blitz.
Moderna put out a press release Wednesday afternoon pointing to two recently unveiled studies that, the biotech asserts, solidify the need for Covid-19 boosters, leaping into the ongoing debate for the shots. The release comes merely hours after briefing documents for the Pfizer/BioNTech adcomm went public, with Moderna putting forth an argument for why its vaccines are better suited to combat the Delta variant than Pfizer and BioNTech’s jab.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
